[#item_full_content] At a White House event where President Trump signed an executive order instructing the DEA to reclassify marijuana as a Schedule III drug, CMS Director Mehmet Oz announced plans to have Medicare pay for specific formulations of CBD. He may be motivated by good intentions, but the plan is at odds with Congress, which recently effectively banned CBD. It might also harm the millions of non-seniors who benefit from CBD by making it less affordable and harder to obtain. 
Read More
